Who We Are
”We are passionate about finding the most promising, innovative companies to deliver key resources they need to bring life-changing therapies to patients desperately in need. We strive to keep the patient at the center of all our decisions and advice.”Chris Jeffers & Josh BarerOrchid Bioventures Founders
Chris received his Ph.D. training in Biochemistry and Biophysics at Rice University and the University of Houston, where he was a National Institutes of Health Predoctoral Fellow. Following his Ph.D. training Chris was an NIH Postdoctoral Fellow at The Johns Hopkins University School of Medicine where he studied the structure of the Cystic Fibrosis Transmembrane Conductance Receptor (CFTR). In addition, Chris obtained his law degree from Georgetown University. Bringing years of startup experience to Orchid Chris was the founder of FirstStage Bioventures, Seguro Surgical, EncephRx and Camden Pharmaceuticals, and was the General Counsel and V.P. of Drug Discovery at Alba Therapeutics. In addition to serving as outside General Counsel to numerous biotech companies including Viela Bio and NexImmune, Chris holds adjunct faculty appointments in the School of Business and Whiting School of Engineering at Johns Hopkins University.
*Note that Dr. Jeffers is not acting as a lawyer in any capacity in his role as Managing Director of Hibiscus BioVentures. As such, no conversations with Dr. Jeffers are privileged, and Dr. Jeffers will not give legal advice through any interaction with Hibiscus BioVentures or any affiliated company.
Prior to HB and B&S, Josh has spent his career at several boutique investment banks and consultancies, including Trout Capital and the Maxim Group, and has a passion for early-stage drug development to serve patients with unmet medical needs. He is also a Venture Advisor at the Israel Biotech Fund (IBF).
Josh is on the boards of Asclepix, Inc. and NexImmune, Inc. (board observer). He is also on the Boards of several-not for-profit organizations focused on education and economic development, including Trickle Up, Family Promise, and Getting Out and Staying Out (Action Board).
Josh received a Bachelor of Arts from Rutgers College and studied Conflict Management at Drew University.
A former management consultant with McKinsey & Company in its Pharmaceutical and Medical Products practice, Michael also has a background in corporate finance and sell-side analyst research, with deep knowledge of the pharmaceutical/biotech industry. Mr. King holds an M.B.A. with Honors from the Columbia Graduate School of Business.
Outside of HB, Khatija is a serial entrepreneur; currently a CEO of BioSapien Inc. BioSapien’s key asset is a 3D printed drug delivery platform.
Khatija is also involved in non-profit work involving building water pumps in South Asia and volunteering at Habitat for Humanity in NYC to build homes globally. Her recent trip was to El Salvador to build a home with Habitat for Humanity. She has served on the Habitat for Young Professionals Board for NYC.
Outside of professional work, most of the time is spent on snow hills, rock walls and race tracks.